Retinoids induce t-PA synthesis by C6 glioma cells - Role in tumoral haemorrhagic necrosis

Thrombosis and Haemostasis

Volumn 75, Issue 2, 1996, Pages 332-338

  Pernod, Gilles ^a   Amalfitano, Guy ^a   Le Magueresse, Brigitte ^b   Berger, François ^a   Polack, Benoit ^a   Kolodié, Lucien ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN; MESSENGER RNA; RETINOID; TISSUE PLASMINOGEN ACTIVATOR; ANTINEOPLASTIC AGENT; RNA; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING DISORDER; BRAIN TUMOR; CONTROLLED STUDY; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION; GLIOMA CELL; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR; ANIMAL; BIOSYNTHESIS; BRAIN HEMORRHAGE; CANCER TRANSPLANTATION; CELL CULTURE; DRUG EFFECT; DRUG SCREENING; FIBRINOLYSIS; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; METABOLISM; NECROSIS; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SUDDEN DEATH;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CEREBRAL HEMORRHAGE; DEATH, SUDDEN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FIBRINOLYSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; ISOTRETINOIN; NECROSIS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; RNA, NEOPLASM; TISSUE PLASMINOGEN ACTIVATOR; TUMOR CELLS, CULTURED;

EID: 0029665458     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650270     Document Type: Article

References (43)

1. Amalfitano G, Berger F, Lainé M, Nisson MF, Verna JM, Benhabid AL. Retinoic acid therapy in the rat C6 glioma model: induction of in vivo redifferentiation and hemorrhagic intra-tumoral side effects. Submitted 1995.
2. Sawaya R, Highsmith R. Plasminogen activator activity and molecular weight patterns in human brain tumors. J Neurosurg 1988; 68: 73-9.
3. Humphries JE, Vasudevan J, Gonias SL. Fibrinogenolytic and fibrinolytic activity of cell-associated plasmin. Arterioscler Thromb 1993; 13: 48-55.
4. Humphries JE, De la Cadena RA, Atkins TL, Colman RW, Gonias SL. Interaction of high molecular weight kininogen with plasminogen to cell surfaces. Fibrinolysis 1994; 8: 245-54.
5. 2-macroglobulin. J Biol Chem 1991; 266: 12329-36.
6. Vaithilingam IS, McDonald W, Brown NK, Stroude E, Cook RA, Del Maestro RF. Serum proteolytic activity during the growth of C6 astrocytoma. J Neurosurg 1992; 77: 595-600.
7. Mignatti P, Robbins E, Rifkin DB.Tumor cell invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 1986; 47: 487-98.
8. Hall SW, Vanderberg SR, Gonias SL. Expression of plasminogen receptors on C6 glioma cells. Brain Res 1989; 495: 373-6.
9. Hall SW, Braud LL, Gonias SL. Binding of bovine, ovine, porcine, canine, and rat plasminogen to rat hepatocytes and rat C6 glioma cells in vitro. Biochem Biophys Res Commun 1989; 164: 1288-94.
10. Benabid AL, Remy C, Chauvin C. Experimental models of rat brain tumors by stereotaxic injection of C6 glioma and HTC hepatoma cell lines. Biology of Brain Tumor. Walker MD, Thomas DGT, eds. Boston: Martinus Nijhoff Publishers, 1986; 221-6.
11. Bernstein JJ, Goldberg WJ, Laws ER, Conger D, Morreale V, Wood LR. C6 glioma cell invasion and migration of rat brain after neural homograftα ing: Ultrastructure. Neurosurg 1990; 26: 622-8.
12. Pernod G, Amalfitano G, Polack B, Mossuz P, Berger F, Kolodié L. t-PA production by C6 glioma cells and effect of retinoid-induced differentiation. XIIth International Congress of fibrinolysis. Fibrinolysis 1994; 8:426 (abstr.).
13. Murphy PG, Hart DA. Regulation of plasminogen activator and plasminogen activator inhibitor expression by cells of neural origin. Sem Thromb Hemost 1991; 17: 268-75.
14. Seeds NW, Verrall S, Friedman G, Hayden S, Gadotti D, Haffke S, Christensen K, Gardner B, McGuire P, Krystosek A. Plasminogen activators and pkasminogen activator inhibitors in neural development. Ann N Y Acad Sci 1992; 667: 32-40.
15. Benjamin LA, McGarry RC, Hart DA. Effect of retinoic acid on human neuroblastoma. Cancer Chemother Pharmacol 1989; 25: 25-31.
16. Thompson EA, Nelles L, Collen D. Effect of retinoic acid on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in human endothelial cells. Eur J Biochem 1991; 201: 627-32.
17. Kooistra T, Opdenberg JP, Toet K, Hendriks HFJ, Van den Hoogen RM, Emeis JJ. Stimulation of tissue-type plasminogen activator synthesis by retinoids in cultured human endothelial cells and rat tissues in vivo. Thromb Haemost 1991; 65: 565-72.
18. Padro T, Van den Hoogen CM, Emeis JJ. Distribution of tissue-type plasminogen activator (activity and antigen) in rat tissues. Blood Coag Fibrinol 1990; 1: 601-8.
19. Van Bennekum AM, Emeis JJ, Kooistra T, Hendriks HFJ. Modulation of tissue-type plasminogen activator by retinoids in rat plasma and tissues. Am J Physiol 1993; 264: R931-7.
20. Van Giezen JJJ, Boon DIA, Jansen JWCM, Bouma BN. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue-type plasminogen activator (t-PA) activity and inhibits venous thrombosis. Thromb Haemost 1993; 69: 381-6.
21. Kobayashi NN, Allen N, Clendenon NR, Li Wen K. An improved rat brain tumor model. J Neurosurg 1980; 53: 808-15.
22. Benda P, Lightbody J, Sato G, Levine L, Sweet W. Differentiated rat glial cell strain in tissue culture. Science 1968; 161: 370-1.
23. Wohlwend A, Belin D, Vassalli J D, Plasminogen activator-specific inhibitors produced by human monocytes/macrophages. J Exp Med 1987; 165: 320-39.
24. Kolodié L, Rachail M. Different molecular weight forms of tissue-type plasminogen activator in ascitic fluid from patients with liver cirrhosis. Fibrinolysis 1988; 2: 245-9.
25. Granelli-Pipemo A, Reich E. A study of proteases and protease-inhibitor complexes in biological fluid. J Exp Med 1978; 148: 223-34.
26. Kolokis N, Rekkas C, Tsandarliotou M, Smokovitis A. Circadian variations of plasminogen activator activity, tissue-type plasminogen activator antigen, plasminogen activator inhibition and plasmin inhibition in rat aorta, heart and brain are influenced by endotoxin or aspirin or endotoxin plus aspirin. Haemost 1995; 25: 106-13.
27. Vassalli JD, Belin D Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 1987; 214: 187-91.
28. Sappino AP, Madani R, Huarte J, Belin D, Kiss JZ, Wohlwend A, Vassalli JD. Extracellular proteolysis in the adult murine brain. J Clin Invest 1993; 92. 679-85.
29. Sappino AP, Huarte J, Vassalli JD, Belin D. Sites of synthesis of urokinase and tissue-factor plasminogen activators in the murine kidney. J Clin Invest 1991; 87. 962-70.
30. Chomczinski P, Sacchi N. Single step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
31. Le Magueresse-Battistoni B, Wolff J, Morera AM, Benhamed M. Fibroblast growth-factor receptor type-1 expression during rat testicular development and its regulation in cultured Sertoli cells. Endocrinol 1994; 135: 2404-11.
32. Declerck PJ, Juhan-Vague I, Felez J, Wiman B. Pathophysiology of fibrinolysis J Int Med 1994; 236: 425-32.
33. Booth NA, Bennett B, Wijngaards G, Grieve JHK. A new lifelong hemorrhagic disorder due to excess plasminogen activator. Blood 1983; 61: 267-75.
34. Aznar J, Estellés A, Vilar V, Reganon E, Espana F, Villa P. Inherited fibrinolytic disorder due to an enhanced plasminogen activator level. Thromb Haemost 1984; 52: 196-200.
35. Stump DC, Taylor FB, Nesheim ME, Giles AR, Dzik WH, Boviil EG. Pathologic fibrinolysis as a cause of clinical bleeding. Sem Thromb Hemost 1990; 16: 260-73.
36. Markus G, Kohger S, Carmolo SM, Modeja J, Ambrus JL, Karakousis K. Plasminogen activator activity in human malignant melanomas. J Natl Cancer Inst 1984; 72: 1213-22.
37. Cajot JF, Kruithof EKO, Schleuning WD, Sordat B, Bachmann F. Plasminogen activators, plasminogen activator inhibitor and procoagulant analyzed in twenty human tumor cell lines. Int J Cancer 1986; 38: 719-27.
38. Grondahl-Hansen J, Ralfkiaer E, Kirkeby L, Kristensen P, Lund LR, Danø K. Localisation of urokinase-type plasminogen activator in stroma cells in adenocarcinomas of the colon in humans. Am J Pathol 1991; 138: 111-7.
39. Danø K, Andreasen PA, Grondhal-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139-266.
40. Pyke C, Kristensen P, Ralfkiaer E, Grondahl-Hansen J, Eriksen J, Blasi F, Danø K. Urokinase-type plasminogen activator is expressed in stroma cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991; 138: 1059-67
41. Sumi Y, Dent MAR, Owen DE, Seeley PJ, Morris RJ. The expression of tissue and urokinase-type plasminogen activators in neural development suggests different modes of proteolytic involvement in neuronal growth. Development 1992; 116. 625-37.
42. Rickles RJ, Darrow AL, Strickland S. Differentiation-responsive elements in the 5′ region of the mouse tissue plasminogen activator gene confer two-stage regulation by retinoic acid and cyclic AMP in teratocarcinoma cells. Mol Cell Biol 1989; 9: 1691-704.
43. Bulens F, Ibanez-Tallon I, Van Acker P, De Vriese A, Nelles L, Belayew A, Collen D. Retinoic acid induction of human tissue-type plasminogen activator gene expression via a direct repeat element (DR5) located at -7 kilo-bases. J Biol Chem 1995; 270: 7167-75.